| answer text |
<p>No such estimate has been made. In response to the shortage of piperacillin-tazobactam,
the Department has been working with national antimicrobial leads through Public Health
England and the Department’s Expert Advisory Group on Antimicrobial Prescribing Resistance
and Healthcare Associated Infections who published guidance on appropriate alternative
treatment options to ensure that any impact on patient care has been minimised. This
guidance provided recommendations on the different broad spectrum antibiotics, or
a combination of narrower spectrum antibiotics that can be used to treat the range
of infections for which piperacillin-tazobactam is licensed.</p>
|
 |
